Advertisement · 728 × 90
#
Hashtag
#BaseEditing
Advertisement · 728 × 90
Post image Post image Post image

Taking the stage now is Mark Dawson of the Peter MacCallum Cancer Centre. His talk is about understanding human pathology with base editing at single-cell resolution.

#VariantEffect26
#BaseEditing
#AtlasOfVariantEffectsAlliance

1 1 0 0
Post image Post image

#AHAS multi-gene #baseediting

nCas9-PmCDA1 → GmAHAS2/3/4 editing

6 lines: P182S/Y, triple-stacked

2S3S4F (triple) → strongest PE resistance (27.99cm, 2.24g vs. WT 9.13cm, 0.17g)

2Y → BS-specific (binding 7.734→6.766 kcal/mol)

2Y3SC → dual PE+BS

Retains IM resistance #Herbicide

0 0 0 0
Preview
Curing the Bystander Effect: A New Base Editing Tool Minimizes Unwanted Edits to DNA Base editing is still a new technology. Alexis Komor is working to improve its efficiency, while lowering unwanted bystander edits. This occurs when a base editor not only edits the desired nucleobase, but edits surrounding bases as well. Komor’s lab has developed a way to minimize bystander edits.

#BaseEditing is still a relatively new #biotechnology. Researchers are working to improve its efficiency, while lowering the incidence of unwanted bystander edits. Alexis Komor’s lab has developed a new tool to do this. Their work appears in Nature Biotechnology https://bit.ly/47IKYHB

1 1 0 0
Post image Post image

#TGFBI #baseediting for #cornealdystrophy

#ABE8e-NG: R124C 91%, R555W 62%

Allele-specific, <0.2% indels, <0.7% bystander, <1.2% off-target

Function restored: TGFBI lysosomal mislocalization reversed

AAV1 = best corneal transduction

Dominant correction ✓

doi.org/10.1167/iovs...

0 0 0 0
Preview
Base editing milestone for familial hypercholesterolemia - Nature Medicine A phase 1 study demonstrates proof-of-concept of liver-targeted PCSK9 base editing for familial hypercholesterolemia, but turning this into a transformative therapy will require stringent optimization of editing efficiency, safety, patient selection and trial design.

A phase 1 study shows feasibility of PCSK9 #BaseEditing for familial hypercholesterolemia, but clinical translation will require optimal editing , safety, patient selection & trial design.
News & Views from Robert Rosenson, Sascha Goonewardena
https://www.nature.com/articles/s41591-026-04220-0

0 0 0 0
Post image Post image

🐟 Codon-optimized base editors enable efficient A→G & C→T editing in Atlantic salmon

ssABE8e & ssCBE4max-SpRY outperform unoptimized versions in ASK cells & embryos.

tyr KO → albino phenotype. Multiple loci validated.

www.cell.com/trends/biote...

#BaseEditing #Aquaculture #CRISPR

1 0 0 0
Post image Post image

New therapeutic Adenine Base Editor (ABE) with minimized off-target effects! 🧬
A study in Protein&Cell by Erwei Zuo’s team introduces ABE8eY149V.
Read more: doi.org/10.1093/proc...
#GeneEditing #BaseEditing #Biotech #sciencenews

0 0 0 0
Preview
Deaminet 2026 - Harris Lab

Anyone attending #Deaminet2026 on January 21-23? Looking forward to catching up on the latest developments in #baseediting and #primeediting!

labs.uthscsa.edu/rsh/deaminet...

@addgene.bsky.social will be sponsoring poster prizes!

#CRISPR #geneediting #GeneAndCellTherapy #CellAndGeneTherapy

0 0 0 1
Preview
Targeted BDNF upregulation via upstream open reading frame disruption To understand the relative contributions of 5ʹ UTR elements to translation output, we performed a comprehensive analysis of upstream open reading fram…

Latest research from my group. We activated BDNF protein expression by disrupting a repressive uORF using a CRISPR base editing strategy: www.sciencedirect.com/science/arti...

#OxfordPaediatrics #IDRMOxford #BDNF #uORF #CRISPR #BaseEditing

8 4 0 0
Video

🌟New hope for vision restoration: Congratulations to Bence György on his 5-year @erc.europa.eu Consolidator Grant. His proposal was selected among 3121 applications from across Europe - a strong vote of confidence in our work at IOB!
#ERCCoG #BaseEditing #VisionResearch #Blindness #AcademicBlueSky

4 0 0 0
Post image

🌟New hope for vision restoration: Warm congratulations to Bence György on his 5-year @erc.europa.eu Consolidator Grant to advance base editing for genetic macular degeneration and explore therapies for corneal blindness.
#ERCCoG #BaseEditing #VisionResearch #Blindness #AcademicBlueSky

2 0 0 0
Preview
Blood cancer therapy reverses incurable leukaemia in some patients Seven out of 11 patients with incurable cancer who had the treatment appear to be cancer-free.

It's always exciting to see pioneering research making the leap into pioneering therapies that have had real long-term success:
www.bbc.co.uk/news/article...

#Research #BaseEditing

0 0 0 0
A base editing platform for the correction of cancer driver mutations unmasks conserved p53 transcription programs

Our #BaseEditing paper is DG-GT’s “Paper of the Quarter”! 🎉

We used precise gene editing to correct cancer mutations in TP53 – and watched as corrected cells nearly vanished. A step toward mRNA therapies for cancer! 💡

Full paper: rdcu.be/exqtH #CancerResearch #GeneEditing #Science #DG_GT

0 0 0 0
Post image

This review highlights recent advances in #Mitochondrial #BaseEditing & its relevance to #NeurodegenerativeDiseases, offering insights into how this technology could inform future strategies for prevention & targeted intervention. #medsky

#OpenAccess: www.sciencedirect.com/science/arti...

0 0 0 0

This paper was truly a team effort, thanks to all who came together and made it happen! #CRISPR #GeneEditing #GenomeEditing #BaseEditing #AdenineBaseEditing

0 0 0 0
Preview
Baby KJ's doctors will ask FDA this winter to OK a clinical trial of pioneering gene editing approach Baby KJ's medical team intend to ask the FDA to start a clinical trial that would be open to patients with seven different urea cycle disorders.

Baby KJ; doctors will ask FDA this winter to OK a clinical trial of pioneering gene editing approach.
#genetherapy
#baseediting
#crispr
#geneediting

www.statnews.com/2025/10/16/b... via @statnews.com

1 0 0 0
Chao and colleagues show an image of glioblastoma (red) treated with CF17 oncolytic virus (green). Image credit: Jianfei Chao.

Chao and colleagues show an image of glioblastoma (red) treated with CF17 oncolytic virus (green). Image credit: Jianfei Chao.

#MolecularTherapy Oncology's Sept 2025 issue covers new research on #Nanobodies, #OncolyticViruses, #BaseEditing, and #TherapeuticTargets in #Cancer. Check it out today: http://dlvr.it/TN8jsh
#ASGCT

1 1 0 0
Diagram illustrating how precise editing of the ZmACC1/2 genes generated herbicide-tolerant maize germplasm, offering a solution for weed management in maize-soybean intercropping systems.

Diagram illustrating how precise editing of the ZmACC1/2 genes generated herbicide-tolerant maize germplasm, offering a solution for weed management in maize-soybean intercropping systems.

🌽#Biotech breakthrough!🧬
Robust #genetic mods without yield loss? Fu et al. show it's possible in new work that enhances #herbicide tolerance in #maize using cytosine and adenine #BaseEditing!

Read the entire article for #free right here!⬇️
doi.org/10.1111/jipb...
#PlantScience #OpenAccess

3 1 0 0
A base editing platform for the correction of cancer driver mutations unmasks conserved p53 transcription programs

Read the full study here:
rdcu.be/exqtH

Lastly, this wouldn't have been possible without a fantastic team of co-authors ☺️ Truly grateful to everyone who contributed and supported the work along the way.

#BaseEditing #PrecisionOncology #TP53 #CRISPR

0 0 0 0
Preview
Precision gene editing medicine makes history, and it’s just getting started - Nature Biotechnology Despite their astounding success, custom-made base editors and prime editors will need time to broaden their clinical impact.

#baseEditing #personalizedMedicine
#precisionGeneEditing

We are there!! 💛🧬

As of June, at least 20 clinical trials with base or prime editors are underway. The newer base and prime editing medicines modify or insert specific nucleotides into the DNA without creating double-stranded breaks.

2 0 0 0
Post image

Proud of Kaisa Pakari @kpakari.bsky.social to receive the 2025 Schmeil young researcher award for her #PhD thesis. She established 🐟 models to address disorders of #glycosylation #CDG by advancing #baseediting range for precise genome editing @wittbrodtlab.bsky.social @cos.uni-heidelberg.de

13 3 1 0
Correction of m.4291T > C in primary patient-derived fibroblasts. Top left: The primary patient-derived fibroblast line is homoplasmic for the m.4291T > C mutation. Top right: Design of two sets of Left (red) and Right (green) target sequences flanking the spacer region (blue) for TALE-guided editing in MT-TI to correct m.4291C > T (dark red). Mismatched T (red) in TALE target sequence L2. Middle: Overview of the transfection strategy of DdCBE for primary skin fibroblasts. Bottom left: Editing efficiencies of all four combinations Left- and Right-TALE-DdCBE plasmids in primary patient-derived fibroblasts as measured by amplicon sequencing (Illumina NGS). Bottom middle: Ratio of on-target editing vs. bystander editing at any other base within the spacing region in fibroblast cells. Bottom right: Clonal lines of edited primary patient-derived fibroblasts show high variability in mitochondrial heteroplasmy indicating different editing efficiencies per cell (Illumina NGS).

Correction of m.4291T > C in primary patient-derived fibroblasts. Top left: The primary patient-derived fibroblast line is homoplasmic for the m.4291T > C mutation. Top right: Design of two sets of Left (red) and Right (green) target sequences flanking the spacer region (blue) for TALE-guided editing in MT-TI to correct m.4291C > T (dark red). Mismatched T (red) in TALE target sequence L2. Middle: Overview of the transfection strategy of DdCBE for primary skin fibroblasts. Bottom left: Editing efficiencies of all four combinations Left- and Right-TALE-DdCBE plasmids in primary patient-derived fibroblasts as measured by amplicon sequencing (Illumina NGS). Bottom middle: Ratio of on-target editing vs. bystander editing at any other base within the spacing region in fibroblast cells. Bottom right: Clonal lines of edited primary patient-derived fibroblasts show high variability in mitochondrial heteroplasmy indicating different editing efficiencies per cell (Illumina NGS).

What is the therapeutic potential of correcting mutations by base editing of the #MitochondrialGenome? This study shows that #mitochondrial #BaseEditing can indeed functionally create & correct mitochondrial pathogenic #mutations in patient-derived cells @plosbiology.org 🧪 plos.io/3ZMa2K2

5 1 0 0
Correction of m.4291T > C in primary patient-derived fibroblasts. Top left: The primary patient-derived fibroblast line is homoplasmic for the m.4291T > C mutation. Top right: Design of two sets of Left (red) and Right (green) target sequences flanking the spacer region (blue) for TALE-guided editing in MT-TI to correct m.4291C > T (dark red). Mismatched T (red) in TALE target sequence L2. Middle: Overview of the transfection strategy of DdCBE for primary skin fibroblasts. Bottom left: Editing efficiencies of all four combinations Left- and Right-TALE-DdCBE plasmids in primary patient-derived fibroblasts as measured by amplicon sequencing (Illumina NGS). Bottom middle: Ratio of on-target editing vs. bystander editing at any other base within the spacing region in fibroblast cells. Bottom right: Clonal lines of edited primary patient-derived fibroblasts show high variability in mitochondrial heteroplasmy indicating different editing efficiencies per cell (Illumina NGS).

Correction of m.4291T > C in primary patient-derived fibroblasts. Top left: The primary patient-derived fibroblast line is homoplasmic for the m.4291T > C mutation. Top right: Design of two sets of Left (red) and Right (green) target sequences flanking the spacer region (blue) for TALE-guided editing in MT-TI to correct m.4291C > T (dark red). Mismatched T (red) in TALE target sequence L2. Middle: Overview of the transfection strategy of DdCBE for primary skin fibroblasts. Bottom left: Editing efficiencies of all four combinations Left- and Right-TALE-DdCBE plasmids in primary patient-derived fibroblasts as measured by amplicon sequencing (Illumina NGS). Bottom middle: Ratio of on-target editing vs. bystander editing at any other base within the spacing region in fibroblast cells. Bottom right: Clonal lines of edited primary patient-derived fibroblasts show high variability in mitochondrial heteroplasmy indicating different editing efficiencies per cell (Illumina NGS).

What is the therapeutic potential of correcting mutations by base editing of the #MitochondrialGenome? This study shows that #mitochondrial #BaseEditing can indeed functionally create & correct mitochondrial pathogenic #mutations in patient-derived cells @plosbiology.org 🧪 plos.io/3ZMa2K2

2 0 0 0
Correction of m.4291T > C in primary patient-derived fibroblasts. Top left: The primary patient-derived fibroblast line is homoplasmic for the m.4291T > C mutation. Top right: Design of two sets of Left (red) and Right (green) target sequences flanking the spacer region (blue) for TALE-guided editing in MT-TI to correct m.4291C > T (dark red). Mismatched T (red) in TALE target sequence L2. Middle: Overview of the transfection strategy of DdCBE for primary skin fibroblasts. Bottom left: Editing efficiencies of all four combinations Left- and Right-TALE-DdCBE plasmids in primary patient-derived fibroblasts as measured by amplicon sequencing (Illumina NGS). Bottom middle: Ratio of on-target editing vs. bystander editing at any other base within the spacing region in fibroblast cells. Bottom right: Clonal lines of edited primary patient-derived fibroblasts show high variability in mitochondrial heteroplasmy indicating different editing efficiencies per cell (Illumina NGS).

Correction of m.4291T > C in primary patient-derived fibroblasts. Top left: The primary patient-derived fibroblast line is homoplasmic for the m.4291T > C mutation. Top right: Design of two sets of Left (red) and Right (green) target sequences flanking the spacer region (blue) for TALE-guided editing in MT-TI to correct m.4291C > T (dark red). Mismatched T (red) in TALE target sequence L2. Middle: Overview of the transfection strategy of DdCBE for primary skin fibroblasts. Bottom left: Editing efficiencies of all four combinations Left- and Right-TALE-DdCBE plasmids in primary patient-derived fibroblasts as measured by amplicon sequencing (Illumina NGS). Bottom middle: Ratio of on-target editing vs. bystander editing at any other base within the spacing region in fibroblast cells. Bottom right: Clonal lines of edited primary patient-derived fibroblasts show high variability in mitochondrial heteroplasmy indicating different editing efficiencies per cell (Illumina NGS).

What is the therapeutic potential of correcting mutations by base editing of the #MitochondrialGenome? This study shows that #mitochondrial #BaseEditing can indeed functionally create & correct mitochondrial pathogenic #mutations in patient-derived cells @plosbiology.org 🧪 plos.io/3ZMa2K2

5 2 0 1
Post image

🧬 EFMC Session at #ChemBioParis2025
"Genome Base Editing & Precision Chemistry for Therapy"
Explore next-gen therapeutics with Claudia Höbartner & Chase Beisel
🎙 Organized by @euromedchem.bsky.social‬
📍 Paris | 🗓 Oct 6–9, 2025
🔗 chembioparis2025.com
#GeneEditing #BaseEditing #ChemBio #MedChem

0 0 0 0
Personalized CRISPR just saved a baby's life
Personalized CRISPR just saved a baby's life YouTube video by WeDoCRISPR

We’re sure you saw the big news last week — personalized CRISPR just saved a baby’s life.

But how did the scientists do it?

In our latest CRISPR180", Antonio Carusillo and Manel Llado break down this amazing research for you in just 3 minutes.

#CRISPR #BaseEditing #RareDisease #GeneEditing

0 0 0 0
Masako Kaufmann and her certificate with the awarded poster on universal CAST-Seq

Masako Kaufmann and her certificate with the awarded poster on universal CAST-Seq

Highlighst of the 2025 ThemeDay:
Congratulations to Masako Kaufmann @uni-freiburg.de for the best poster at the #DGGTeV #Themeday2025 for her work on #BaseEditing #offtarget detection via universal CAST-Seq

0 0 0 0
Post image Post image

Exciting opportunity for @astarsg.bsky.social student @cggoh.bsky.social to exchange new ideas on #CRISPR and #BaseEditing with @spjacksongroup.bsky.social alumnus Dan Durocher @durocher1.bsky.social, with postdoc Dr Simon Lam at #CRISPR25 @eventswcs.bsky.social

8 2 0 0
Preview
Precision genome editing and in-cell measurements of oxidative DNA damage repair enable functional and mechanistic characterization of cancer-associated MUTYH variants Abstract. Functional characterization of genetic variants has the potential to advance the field of precision medicine by enhancing the efficacy of current

I am ecstatic to share this work, which involved functional interrogation of MUTYH variants using base editing. I enjoyed working with Dr. Carlos Vasquez on this project and look forward to seeing this expanded for high throughput!
#baseediting #womeninstem 🧪

academic.oup.com/nar/article/...

4 0 0 0
Preview
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administ... U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -...

Following on the heels of #VerveTherapeutics with VERVE-102, #BeamTherapeutics also got IND clearance from FDA for its #BaseEditing therapeutic: finance.yahoo.com/news/beam-th...

1 0 0 0